{"transactions":[{"id":4637271,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-07T21:11:47.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":272,"price":13.6104,"value":3702.0288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":709153,"source":{"system":"sec-edgar","filing":"0001193125-26-417068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526417068/ownership.xml","form_type":"4"}},{"id":4637270,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-07T21:11:47.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":58061,"price":12.9215,"value":750235.2115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":709425,"source":{"system":"sec-edgar","filing":"0001193125-26-417068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526417068/ownership.xml","form_type":"4"}},{"id":4624954,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":58066,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":4624953,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":13.65,"value":22317.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":4624952,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":4619813,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-16T21:13:54.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":58333,"price":13.903,"value":811003.699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":767486,"source":{"system":"sec-edgar","filing":"0001193125-26-393243","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526393243/ownership.xml","form_type":"4"}},{"id":3522,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":2959,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":584},"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":3521,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":584,"price":14,"value":8176.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":3520,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":584,"price":6.49,"value":3790.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":9201,"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":678476,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":217500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678475,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":25927,"price":16.4173,"value":425651.3371,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":825819,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678474,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":43149,"price":15.3566,"value":662621.9334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":851746,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678473,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":4.14,"value":207000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."}],"balance_after":894895,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":685696,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":59701,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685695,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":61336,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685694,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":12.2,"value":19947.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685693,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685692,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":12,"value":19620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685691,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":695260,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-05T20:10:51.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":26842,"price":10.2301,"value":274596.3442,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":844895,"source":{"system":"sec-edgar","filing":"0001193125-26-335115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526335115/ownership.xml","form_type":"4"}},{"id":696790,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-04T20:45:29.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":12415,"price":10.0461,"value":124722.3315,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":871737,"source":{"system":"sec-edgar","filing":"0001193125-26-333014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526333014/ownership.xml","form_type":"4"}},{"id":709524,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":442,"price":12.8355,"value":5673.291,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":884152,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":709523,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":15283,"price":12.0107,"value":183559.5281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":884594,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":709522,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":42608,"price":12.8656,"value":548177.4848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":899877,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":718483,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":5752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":3543,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":5752},"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718482,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":62971,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":814},"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718481,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":6566,"price":14,"value":91924.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718480,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":5752,"price":6.49,"value":37330.48,"ownership":{"direct":true},"balance_after":15183,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718479,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":814,"price":4.14,"value":3369.96,"ownership":{"direct":true},"balance_after":9431,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":726658,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":63785,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":9810},"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":726657,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":9810,"price":12,"value":117720.0,"ownership":{"direct":true},"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":726656,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":9810,"price":4.14,"value":40613.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":18427,"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":728577,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-23T20:19:06.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":114746,"price":10.4653,"value":1200851.3138,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":942485,"source":{"system":"sec-edgar","filing":"0001834021-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000002/ownership.xml","form_type":"4"}},{"id":731663,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:43:00.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000119312526276168/ownership.xml","form_type":"4"}},{"id":731650,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36685,"kind":"person","name":"THEUER CHARLES","position":1,"cik":"0001631338","reported_name":"THEUER CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:41:31.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631338/000119312526276166/ownership.xml","form_type":"4"}},{"id":731649,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:40:18.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276163","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526276163/ownership.xml","form_type":"4"}},{"id":731647,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:39:01.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526276160/ownership.xml","form_type":"4"}},{"id":731809,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":16046,"kind":"person","name":"MILLIGAN JOHN F","position":1,"cik":"0001191589","reported_name":"MILLIGAN JOHN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:32:39.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":75000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-276149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191589/000119312526276149/ownership.xml","form_type":"4"}},{"id":731794,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:30:44.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000119312526276144/ownership.xml","form_type":"4"}},{"id":732062,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36806,"kind":"person","name":"Chacko Jacob","position":1,"cik":"0001608936","reported_name":"Chacko Jacob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:28:46.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608936/000119312526276138/ownership.xml","form_type":"4"}},{"id":754024,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-02T20:48:55.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1922,"price":10.0197,"value":19257.8634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1057231,"source":{"system":"sec-edgar","filing":"0001193125-26-253740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526253740/ownership.xml","form_type":"4"}},{"id":826073,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:30:07.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":750000,"derivative":{"exercise_price":9.88,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001193125-26-129156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526129156/ownership.xml","form_type":"4"}},{"id":826507,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:30:03.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":217000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":217000,"derivative":{"exercise_price":9.88,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":217000},"source":{"system":"sec-edgar","filing":"0001193125-26-129155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526129155/ownership.xml","form_type":"4"}},{"id":826836,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":55696,"kind":"person","name":"Simms Christopher Paul","position":1,"cik":"0001877012","reported_name":"Simms Christopher Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T16:30:02.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":219000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":219000,"derivative":{"exercise_price":9.88,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":219000},"source":{"system":"sec-edgar","filing":"0001193125-26-129154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877012/000119312526129154/ownership.xml","form_type":"4"}},{"id":829639,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Restricted Stock Units","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":false,"shares":221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."}],"balance_after":3087,"derivative":{"underlying":"Common Stock","underlying_shares":221},"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":829638,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Restricted Stock Units","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":false,"shares":865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."}],"balance_after":12119,"derivative":{"underlying":"Common Stock","underlying_shares":865},"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":829637,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"sale","planned":false,"acquired":false,"shares":80,"price":8.61,"value":688.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":47055,"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":829636,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":true,"shares":221,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":47135,"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":829635,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"sale","planned":false,"acquired":false,"shares":310,"price":8.61,"value":2669.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":46914,"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":829634,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2026-03-24T18:30:41.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":true,"shares":865,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":47224,"source":{"system":"sec-edgar","filing":"0001193125-26-122341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312526122341/ownership.xml","form_type":"4"}},{"id":944175,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-08T02:12:50.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option vest on the first anniversary measured from January 5 2026 (the \"Vesting Commencement Date\"), and 1/36th of the total number of shares vest in twenty-four (24) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":45000,"derivative":{"exercise_price":7.3,"expiration_date":"2036-01-04","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-26-006809","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000119312526006809/ownership.xml","form_type":"4"}},{"id":959934,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Restricted Stock Units","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"exercise","planned":false,"acquired":false,"shares":220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."}],"balance_after":3308,"derivative":{"underlying":"Common Stock","underlying_shares":220},"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":959933,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Restricted Stock Units","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"exercise","planned":false,"acquired":false,"shares":866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company."}],"balance_after":12984,"derivative":{"underlying":"Common Stock","underlying_shares":866},"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":959932,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"sale","planned":false,"acquired":false,"shares":79,"price":8.68,"value":685.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":46359,"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":959931,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"exercise","planned":false,"acquired":true,"shares":220,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":46438,"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":959930,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"sale","planned":false,"acquired":false,"shares":310,"price":8.68,"value":2690.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":46218,"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":959929,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":56340,"kind":"person","name":"Gupta Ashoo","position":1,"cik":"0002091461","reported_name":"Gupta Ashoo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Common Stock","published_at":"2025-12-23T21:05:45.000Z","date":"2025-12-20","kind":"exercise","planned":false,"acquired":true,"shares":866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":46528,"source":{"system":"sec-edgar","filing":"0001193125-25-331299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091461/000119312525331299/ownership.xml","form_type":"4"}},{"id":962165,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":73595,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":962164,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.9,"value":17821.5,"ownership":{"direct":true},"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":962163,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":5229,"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":967047,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36685,"kind":"person","name":"THEUER CHARLES","position":1,"cik":"0001631338","reported_name":"THEUER CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T21:35:36.000Z","date":"2025-12-12","kind":"exercise","planned":false,"acquired":false,"shares":9333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.14,"expiration_date":"2026-03-09","underlying":"Common Stock","underlying_shares":9333},"source":{"system":"sec-edgar","filing":"0001193125-25-320992","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631338/000119312525320992/ownership.xml","form_type":"4"}},{"id":967046,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36685,"kind":"person","name":"THEUER CHARLES","position":1,"cik":"0001631338","reported_name":"THEUER CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:35:36.000Z","date":"2025-12-12","kind":"exercise","planned":false,"acquired":true,"shares":9333,"price":1.14,"value":10639.62,"ownership":{"direct":true},"balance_after":41684,"source":{"system":"sec-edgar","filing":"0001193125-25-320992","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631338/000119312525320992/ownership.xml","form_type":"4"}},{"id":972756,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":71808,"kind":"person","name":"Humer Kristian","position":1,"cik":"0001872280","reported_name":"Humer Kristian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-11T16:18:02.000Z","date":"2025-12-09","kind":"grant","planned":false,"acquired":true,"shares":480000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":480000,"derivative":{"exercise_price":10.51,"expiration_date":"2035-12-08","underlying":"Common Stock","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001193125-25-315989","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872280/000119312525315989/ownership.xml","form_type":"4"}},{"id":994120,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":75230,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":994119,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.59,"value":17314.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":994118,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5229,"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":1013292,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":false,"shares":1084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":9295,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":1084},"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1013291,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"sale","planned":true,"acquired":false,"shares":2678,"price":12,"value":32136.0,"ownership":{"direct":true},"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1013290,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":true,"shares":1084,"price":6.49,"value":7035.16,"ownership":{"direct":true},"balance_after":6272,"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1015887,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":76865,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1015886,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.17,"value":16627.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5188,"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1015885,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":6823,"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1019400,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-14T20:04:10.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":2408,"price":10,"value":24080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5188,"source":{"system":"sec-edgar","filing":"0001193125-25-238995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525238995/ownership.xml","form_type":"4"}},{"id":1031817,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-09-27T01:50:32.000Z","date":"2025-09-23","kind":"sale","planned":true,"acquired":false,"shares":2407,"price":8,"value":19256.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 3,222 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":7596,"source":{"system":"sec-edgar","filing":"0001193125-25-221028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525221028/ownership.xml","form_type":"4"}},{"id":1104989,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36806,"kind":"person","name":"Chacko Jacob","position":1,"cik":"0001608936","reported_name":"Chacko Jacob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:05:35.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1608936/000095017025088497/ownership.xml","form_type":"4"}},{"id":1104580,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:05:18.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088496","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088496/ownership.xml","form_type":"4"}},{"id":1104600,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:04:56.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000095017025088489/ownership.xml","form_type":"4"}},{"id":1104583,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36685,"kind":"person","name":"THEUER CHARLES","position":1,"cik":"0001631338","reported_name":"THEUER CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:04:33.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631338/000095017025088487/ownership.xml","form_type":"4"}},{"id":1104579,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:04:06.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088486/ownership.xml","form_type":"4"}},{"id":1104805,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":16046,"kind":"person","name":"MILLIGAN JOHN F","position":1,"cik":"0001191589","reported_name":"MILLIGAN JOHN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:03:35.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":33750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":33750,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":33750},"source":{"system":"sec-edgar","filing":"0000950170-25-088484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191589/000095017025088484/ownership.xml","form_type":"4"}},{"id":1215369,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:00:20.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":78500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0000950170-25-036696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017025036696/ownership.xml","form_type":"4"}},{"id":1214431,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:58:59.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":267500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":267500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":267500},"source":{"system":"sec-edgar","filing":"0000950170-25-036688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025036688/ownership.xml","form_type":"4"}},{"id":1214432,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:58:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":92300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":92300,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":92300},"source":{"system":"sec-edgar","filing":"0000950170-25-036686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025036686/ownership.xml","form_type":"4"}},{"id":1215351,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:57:50.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":130000,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000950170-25-036685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000095017025036685/ownership.xml","form_type":"4"}},{"id":1214430,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82186,"kind":"person","name":"Kamal Fariborz","position":1,"cik":"0001834020","reported_name":"Kamal Fariborz","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:56:53.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":178400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":178400,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":178400},"source":{"system":"sec-edgar","filing":"0000950170-25-036683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025036683/ownership.xml","form_type":"4"}},{"id":1336914,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2024-12-10T21:28:28.000Z","date":"2024-12-09","kind":"other","planned":false,"acquired":true,"shares":535000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 9, 2024, RA Capital Healthcare Fund, L.P. (the \"Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 9, 2024, RA Capital Healthcare Fund, L.P. (the \"Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of\nthe Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":3610000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":535000},"source":{"system":"sec-edgar","filing":"0001415889-24-028837","document":"form4-12102024_091224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000141588924028837/form4-12102024_091224.xml","form_type":"4"}},{"id":1336913,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T21:28:28.000Z","date":"2024-12-09","kind":"other","planned":false,"acquired":false,"shares":535000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 9, 2024, RA Capital Healthcare Fund, L.P. (the \"Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of\nthe Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4563211,"source":{"system":"sec-edgar","filing":"0001415889-24-028837","document":"form4-12102024_091224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000141588924028837/form4-12102024_091224.xml","form_type":"4"}},{"id":1367388,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":240000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367387,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":2378000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2378000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":2378000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367386,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":3062000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3062000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":3062000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367385,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":87911,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367384,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":2378000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":662970,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367383,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":3062000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":830237,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1403821,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":10379,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1403820,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":500,"price":16.33,"value":8165.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1403819,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1426662,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":10879,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1426661,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":500,"price":15,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1426660,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1451924,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":32502,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}}],"next_cursor":"2024-07-19T00:22:41.000000Z,1451924"}